Valeant Pharmaceuticals International, Inc.·4

Jun 13, 2:52 PM ET

Loberg Philip Walden Jr 4

4 · Valeant Pharmaceuticals International, Inc. · Filed Jun 13, 2011

Insider Transaction Report

Form 4
Period: 2011-06-09
Loberg Philip Walden Jr
EVP, Interim CFO
Transactions
  • Purchase

    Common Stock, no par value

    2011-06-09$52.82/sh+7,500$396,150137,565 total
Footnotes (2)
  • [F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.64 to $53.00, inclusive. The reporting person undertakes to provide to the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F2]This number includes 20,694 Performance based Restricted Share Units that were previously reported in Table I.

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT